E&G Advisors LP Reduces Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

E&G Advisors LP lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,429 shares of the biopharmaceutical company’s stock after selling 400 shares during the period. E&G Advisors LP’s holdings in Gilead Sciences were worth $1,610,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. nVerses Capital LLC acquired a new stake in Gilead Sciences during the third quarter valued at approximately $25,000. HHM Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the period. Valued Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the period. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $29,000. Finally, Crews Bank & Trust purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $31,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.2 %

Shares of NASDAQ GILD opened at $98.38 on Tuesday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $99.45. The firm has a 50 day moving average price of $92.42 and a 200 day moving average price of $85.96. The stock has a market cap of $122.61 billion, a P/E ratio of 1,093.11, a P/E/G ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the previous year, the business posted $2.29 EPS. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis. Analysts expect that Gilead Sciences, Inc. will post 4.34 EPS for the current year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 598,414 shares of company stock valued at $55,953,200 in the last quarter. 0.29% of the stock is currently owned by insiders.

Analysts Set New Price Targets

GILD has been the subject of several recent research reports. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Truist Financial boosted their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Sanford C. Bernstein began coverage on Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price for the company. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Finally, Piper Sandler raised their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.